Success Stories: Vietnamese Postdoctoral Research Fellow Secures EB1A Approval for Cancer Biology Contributions
Client’s Testimonial:
“I am highly satisfied with the professional guidance and assistance of the wegreened I-140 team to during preparation of the I-140 petion which resulted in the EB1A approval in such a short period of time. They have perfectly outlined and emphasized my research in a fascinating way. I am happy to recommend Wegreened service to anyone in need of a professional service regarding Employment-based petition. Wonderful Job! Thank you!”
On September 4th, 2025, we received another EB1A (Alien of Extraordinary Ability) approval for a Postdoctoral Research Fellow in the field of Bioinformatics (Approval Notice).
General Field: Bioinformatics
Position at the Time of Case Filing: Postdoctoral Research Fellow
Country of Origin: Vietnam
State of Residence at the Time of Filing: Texas
Approval Notice Date: September 4th, 2025
Processing Time: 16 days (Premium Processing Requested)
Case Summary:
We are pleased to share the EB1A approval of a postdoctoral research fellow from Vietnam. At the time of filing, he was conducting research in the United States on bioinformatics and cancer biology, advancing computational oncology and precision medicine. His extensive publication record, high citation impact, and sustained service as a reviewer and editor established him as a persuasive candidate for EB1A approval.
Extraordinary Research with Global Impact
The client’s contributions span identifying cancer-specific expression patterns of calcium channels, discovering biomarkers and therapeutic targets in breast cancer, and applying deep learning and multimodal AI approaches to improve cancer prognosis. His findings have been adopted in studies of kidney cancer genetics, immune evasion in gastric cancer, and breast cancer histology, demonstrating a wide-ranging impact on oncology and personalized medicine.
Well Positioned to Advance the Field
The client holds a Ph.D. in bioinformatics and has authored 48 peer-reviewed journal articles, 15 of them as first or co-first author, along with 2 conference abstracts. His work has been cited over 1,800 times by independent researchers, with at least 10 papers ranked among the most highly cited in molecular biology and genetics for their publication years. His citation record places him among the top 1 percent of computational science authors and the top 2 percent of bioinformatics researchers worldwide.
Beyond publications, he has completed more than 20 peer reviews for respected journals such as Computers in Biology and Medicine and npj Precision Oncology. He also serves on editorial boards for PLOS ONE, Discover Oncology, Frontiers in Bioinformatics, and Frontiers in Oncology, underscoring his recognition as a trusted authority in the field.
Recognition from Field Experts
Independent recommenders confirmed the originality and importance of his work.
One expert noted:
“Above all, [client]’s contributions are essential to the United States’ efforts to advance personalized cancer treatment, improve diagnostic accuracy, and develop next-generation therapeutic strategies that address the growing burden of cancer-related public health challenges.”
This endorsement highlights how his research bridges scientific innovation with pressing clinical needs.
EB1A Approval and Outlook
The I-140 EB1A petition was filed on August 19, 2025, upgraded to premium processing, and approved on September 4, 2025. USCIS recognized his publication record, international citation impact, peer review and editorial service, and his highly regarded research as sufficient to satisfy the EB1A standard.
With NAILG’s guidance, the client secured EB1A approval and is now positioned to continue his critical research in bioinformatics and cancer biology. His ongoing research promises to advance precision oncology, improve patient outcomes, and reinforce U.S. leadership in biomedical innovation.